The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy ...

• Main Authors: Jonsson, Maria, Hensvold, Aase, Hansson, Monika, Aga, Anna-Birgitte, Sexton, Joseph, Mathsson-Alm, Linda, Cornillet, Martin, Serre, Guy, Lillegraven, Siri, Fevang, Bjørg-Tilde, Catrina, Anca, Haavardsholm, Espen
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: figshare 2018
• Subjects: Biochemistry; Medicine; Genetics; FOS: Biological sciences; Biotechnology; Ecology; Immunology; FOS: Clinical medicine; Infectious Diseases; FOS: Health sciences; Arctic
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.4163894.v1; https://springernature.figshare.com/collections/The_role_of_anti-citrullinated_protein_antibody_reactivities_in_an_inception_cohort_of_patients_with_rheumatoid_arthritis_receiving_treat-to-target_therapy/4163894/1

Abstract Background Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception cohort of patients with early RA, and to investigate their associations with disease activity, treatment response, ultrasound findings and radiographic damage. Methods Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone bridging. Analysis of 16 different ACPA reactivities targeting ...